DOI QR코드

DOI QR Code

Therapeutic monitoring of vancomycin according to initial dosing regimen in pediatric patients

  • Kim, Dae-Il (Department of Pediatrics, Seoul National University College of Medicine) ;
  • Im, Mi-Sun (Department of Pediatrics, Seoul National University College of Medicine) ;
  • Choi, Jin-Hyoung (Department of Pediatrics, Seoul National University College of Medicine) ;
  • Lee, Jin-A (Department of Pediatrics, Seoul National University College of Medicine) ;
  • Choi, Eun Hwa (Department of Pediatrics, Seoul National University College of Medicine) ;
  • Lee, Hoan-Jong (Department of Pediatrics, Seoul National University College of Medicine)
  • Received : 2010.08.16
  • Accepted : 2010.10.29
  • Published : 2010.12.15

Abstract

Purpose: This study aimed to determine the optimal initial vancomycin dose to achieve appropriate trough levels in pediatric patients. Methods: We analyzed clinical data for 309 children treated with intravenous vancomycin between 2004 and 2009 at 2 different hospitals in South Korea. The patients were 1-16 years old and exhibited normal renal function. Patient data, including reason for treatment and initial dosing regimen, were reviewed. Two subgroups were identified and compared according to initial vancomycin dose: 40 (35-45) mg/kg/day and 60 (55-65) mg/kg/day. Trough levels were obtained at steady state after at least 4 doses of vancomycin. Results: Patients who received vancomycin had post-operation or wound-related infections (37.2%), localized infection (12.9%), catheter-related infections (9.4%), meningitis (8.7%), or endocarditis (6.8%). Pathogens were confirmed in 79 cases: 28 cases of methicillin-resistant $Staphylococcus$ $epidermidis$ (35.4%) and 25 of methicillin-resistant $Staphylococcus$ $aureus$ (31.6%). Out of the 309 patients, 201 (65%) received vancomycin at 40 mg/kg/day and 108 (35%) at 60 mg/kg/day. Average trough concentrations were significantly different between the groups ($P$<0.001). Trough levels over 10 mg/L were less likely to be achieved in the 40 mg/kg/day group (14%) than in the 60 mg/kg/day group (49%) ($P$<0.001). There were no differences in renal function deterioration between the groups. Conclusion: A common vancomycin dosing regimen, 40 mg/kg/day, was not high enough to achieve trough levels of over 10 mg/L in pediatric patients. Careful drug monitoring must be performed, and increasing initial dose of vancomycin should be considered in pediatric patients.

Keywords

References

  1. Hazlewood KA, Brouse SD, Pitcher WD, Hall RG. Vancomycin associated nephrotoxicity: grave concern or death by character assassination? Am J Med 2010;123:182.e1-7. https://doi.org/10.1016/j.amjmed.2009.05.031
  2. Kaplan SL, Hulten KG, Gonzalez BE, Hammerman WA, Lamberth L, Versalovic J, et al. Three-year surveillance of community-acquired Staphylococcus aureus infections in children. Clin Infect Dis 2005;40:1785-91. https://doi.org/10.1086/430312
  3. Sakoulas G, Moellering RC Jr. Increasing antibiotic resistance among methicillin-resistant Staphylococcus aureus strains. Clin Infect Dis 2008;46:S360-7. https://doi.org/10.1086/533592
  4. Musta AC, Riederer K, Shemes S, Chase P, Jose J, Johnson LB, et al. Vancomycin MIC plus heteroresistance and outcome of methicillin-resistant Staphylococcus aureus bacteremia: trends over 11 years. J Clin Microbiol 2009;47:1640-4. https://doi.org/10.1128/JCM.02135-08
  5. Kollef MH. Limitations of vancomycin in the management of resistant staphylococcal infections. Clin Infect Dis 2007;45:S191-5. https://doi.org/10.1086/519470
  6. Hermsen ED, Hanson M, Sankaranarayanan J, Stoner JA, Florescu MC, Rupp ME. Clinical outcomes and nephrotoxicity associated with vancomycin trough concentrations during treatment of deep-seated infections. Expert Opin Drug Saf 2010;9:9-14. https://doi.org/10.1517/14740330903413514
  7. Taketomo CK, Hodding JH, Kraus DM. Pediatric Dosage Handbook. 14th ed. Hudson, OH:Lexi-Comp, 2007: 1596-8.
  8. Schaad UB, McCracken GH Jr, Nelson JD. Clinical pharmacology and efficacy of vancomycin in pediatric patients. J Pediatr 1980;96:119-26. https://doi.org/10.1016/S0022-3476(80)80347-7
  9. Patanwala AE, Norris CJ, Nix DE, Kopp BJ, Erstad BL. Vancomycin dosing for pneumonia in critically ill trauma patients. J Trauma 2009;67:802-4. https://doi.org/10.1097/TA.0b013e31818e90d2
  10. Geraci JE. Vancomycin. Mayo Clin Proc 1977;52:631-4.
  11. Ambrose P, Winter ME. Vancomycin. Basic Clinical Pharmacokinetics. 4th ed. Philadelphia: Lippincott Williams and Wilkins, 2004:451-76.
  12. Rybak M, Lomaestro B, Rotschafer JC, Moellering R Jr, Craig W, Billeter M, et al. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm 2009;66:82-98. https://doi.org/10.2146/ajhp080434
  13. Pillai SK, Wennersten C, Venkataraman L, Eliopoulos GM, Moellering RC, Karchmer AW. Development of reduced vancomycin susceptibility in methicillin-susceptible Staphylococcus aureus. Clin Infect Dis 2009;49:1169-74. https://doi.org/10.1086/605636
  14. Levine DP. Vancomycin: a history. Clin Infect Dis 2006;42:S5-12. https://doi.org/10.1086/491709
  15. Frymoyer A, Hersh AL, Benet LZ, Guglielmo BJ. Current recommended dosing of vancomycin for children with invasive methicillin-resistant Staphylococcus aureus infections is inadequate. Pediatr Infect Dis J 2009;28:398-402. https://doi.org/10.1097/INF.0b013e3181906e40
  16. Cunha BA. Vancomycin. Med Clin North Am 1995;79:817-31. https://doi.org/10.1016/S0025-7125(16)30041-4
  17. Cunha BA. Vancomycin revisited: A reappraisal of clinical use. Crit Care Clin 2008;24:393-420. https://doi.org/10.1016/j.ccc.2007.12.012
  18. American Thoracic Society; Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005;171:388-416. https://doi.org/10.1164/rccm.200405-644ST
  19. Moise-Broder PA, Forrest A, Birmingham MC, Schentag JJ. Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infection. Clin Pharmacokinet 2004;43:925-42. https://doi.org/10.2165/00003088-200443130-00005
  20. Charles PG, Ward PB, Johnson PD, Howden BP, Grayson ML. Clinical features associated with bacteremia due to heterogeneous vancomycin-intermediate Staphylococcus aureus. Clin Infect Dis 2004;38:448-51. https://doi.org/10.1086/381093
  21. Sakoulas G, Gold HS, Cohen RA, Venkataraman L, Moellering RC, Eliopoulos GM. Effects of prolonged vancomycin administration on methicillin-resistant Staphylococcus aureus (MRSA) in a patient with recurrent bacteraemia. J Antimicrob Chemother 2006;57:699-704. https://doi.org/10.1093/jac/dkl030
  22. Howden BP, Ward PB, Charles PG, Korman TM, Fuller A, du Cros P, et al. Treatment outcome for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility. Clin Infect Dis 2004;38:521-8. https://doi.org/10.1086/381202
  23. Chang D. Influence of malignancy on the pharmacokinetics of vancomycin in infants and children. Pediatr Infect Dis J 1995;14:667-73. https://doi.org/10.1097/00006454-199508000-00004
  24. Glover ML, Cole E, Wolfsdorf J. Vancomycin dosage requirements among pediatric intensive care unit patients with normal renal function. J Crit Care 2000;15:1-4. https://doi.org/10.1053/jcrc.2000.0150001
  25. Pea F, Porreca L, Baraldo M, Furlanut M. High vancomycin dosage regimens required by intensive care unit patients cotreated with drugs to improve haemodynamics following cardiac surgical procedures. J Antimicrob Chemother 2000;45:329-35. https://doi.org/10.1093/jac/45.3.329
  26. Nivoche Y, Contrepois A, Cremieux AC, Carbon C. Vancomycin in rabbits: pharmacokinetics, extravascular diffusion, renal excretion and interactions with furosemide. J Pharmacol Exp Ther 1982;222:237-40.
  27. Pea F, Furlanut M. Pharmacokinetic aspects of treating infections in the intensive care unit. Clin Pharmacokinet 2001;40:833-68. https://doi.org/10.2165/00003088-200140110-00004
  28. Jeffres MN, Isakow W, Doherty JA, McKinnon PS, Ritchie DJ, Micek ST, et al. Predictor of mortality for methicillin resistant Staphylococcus aureus healthcare-associated pneumonia: specific evaluation of vancomycin pharmacokinetic indices. Chest 2006;130:947-55. https://doi.org/10.1378/chest.130.4.947
  29. Hidayat LK, Hsu DI, Quist R, Shriner KA, Wong-Beringer A. High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity. Arch Intern Med 2006;166:2138-44. https://doi.org/10.1001/archinte.166.19.2138

Cited by

  1. The Effect of Age and Weight on Vancomycin Serum Trough Concentrations in Pediatric Patients vol.33, pp.12, 2010, https://doi.org/10.1002/phar.1331
  2. Improved Vancomycin Dosing in Children Using Area Under the Curve Exposure vol.32, pp.4, 2010, https://doi.org/10.1097/inf.0b013e318286378e
  3. Assessment of Therapeutic Drug Monitoring of Vancomycin in Elderly Patients According to New Guidelines vol.34, pp.1, 2010, https://doi.org/10.3343/alm.2014.34.1.1
  4. Evaluation of Vancomycin Dosing and Corresponding Drug Concentrations in Pediatric Patients vol.4, pp.6, 2010, https://doi.org/10.1542/hpeds.2014-0019
  5. Validation of a Pediatric Population Pharmacokinetic Model for Vancomycin vol.37, pp.3, 2010, https://doi.org/10.1097/ftd.0000000000000153
  6. Evaluation of Target Attainment of Vancomycin Area Under the Curve in Children With Methicillin-Resistant Staphylococcus Aureus Bacteremia vol.37, pp.5, 2015, https://doi.org/10.1097/ftd.0000000000000190
  7. Trough Concentrations of Vancomycin in Patients Undergoing Extracorporeal Membrane Oxygenation vol.10, pp.11, 2015, https://doi.org/10.1371/journal.pone.0141016
  8. Guidelines for Therapeutic Drug Monitoring of Cardiovascular Drugs Clinical Use of Blood Drug Concentration Monitoring (JCS 2015) ― Digest Version ― vol.81, pp.4, 2010, https://doi.org/10.1253/circj.cj-66-0138
  9. Vancomycin Therapeutic Regime Adjustment in Newborns and Infants with Bacterial Infection: Case Series vol.20, pp.4, 2010, https://doi.org/10.2174/1389201020666190319161511
  10. Association of Initial Trough Concentrations of Vancomycin with Outcomes in Pediatric Patients with Gram-Positive Bacterial Infection vol.43, pp.10, 2010, https://doi.org/10.1248/bpb.b19-01003